Taragenyx announces appointment of Stewart White to board of directors

- CEO of AIM listed medical technologies company joins Taragenyx board -

Glasgow, Scotland - November 05, 2015

Orthopaedic biotechnology company, Taragenyx Ltd., today announced that Dr Stewart White, CEO of AIM Listed Collagen Solutions (LSE:COS), has been elected to the Taragenyx Board of Directors.

White brings recent and direct Board experience of leading an AIM quoted company, having successfully brought Collagen Solutions onto the London Stock Exchange on the 2nd January 2014. Collagen Solutions is a global provider of medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics.

“Stewart is one of only a handful of CEO’s here in Scotland who have successfully led a lifescience company onto the public markets and we are very excited to welcome him onto our Board of Directors,” said Iain McDougall, CEO of Taragenyx. “We believe his strong experience in product development, operations, and especially in M&A to build a global business, will be extremely valuable as Taragenyx continues to grow.”

“We conducted an exhaustive search for someone who would further strengthen our Board’s breadth of talent and background, and we are delighted to have identified such an outstanding individual,” said Raman Bedi, Founder and Chairman of Taragenyx. “As we continue to explore new areas for growth, Stewart’s expertise and strategic insight will be of tremendous value to our Board and to Taragenyx.”

“I’m thrilled and honored to be joining the Taragenyx Board,” said White. “Their market focus on hard tissue therapies and their public market ambitions align perfectly with my own experience. I look forward to helping them continue their forward-thinking mission with my fellow board members and the Taragenyx Executive team.”

White is a graduate of the University of Strathclyde and holds a First Class degree in Applied Microbiology, a Ph.D. in Fermentation Technology and Bioprocessing, and an MBA. He has international experience in operations, business and product development, and compliant manufacturing of collagen medical devices, advanced biologics and Active Pharmaceutical Ingredients in both Small to Medium Enterprises as well as global pharmaceutical companies.

Taragenyx has pioneered the development of self-healing therapeutic implants aimed at tackling the incredibly painful and expensive problem of orthopaedic implant failure. They are the youngest and only biotech company on the prestigious London Stock Exchange ELITE Program for high growth businesses.